Given its pivotal role in cell cycle regulation, Cyclin A is a significant biomarker in oncology. Elevated levels of Cyclin A have been observed in various cancers, including breast, colorectal, and lung cancer. Targeting Cyclin A or its associated CDKs offers a potential therapeutic strategy for cancer treatment.
